It is also an issue affecting patients who had started losing weight but then are not able to continue taking the medication and start to gain weight again, she says
Compounding the problem is the fact that insurance companies are reluctant to cover these anti-obesity medications, since theyre considered by many to be vanity drugs, even though overwhelming evidence suggests obesity is linked directly to multiple comorbidities
Other Innovative Solutions To further support our clients and their members, we created our Diabetes Care Plus program
More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1. Seeking confirmation The results were so surprising, Gloyns team spent the next several years confirming them
As shortages of brand-name GLP-1 medications begin to ease, regulators are increasing scrutiny on these platforms to ensure patient safety and compliance, signaling a broader crackdown on unapproved or gray-market weight-loss treatments
Teaming up with researchers in Copenhagen, they showed that a PAM defect does not alter the GLP-1 receptors ability to bind GLP-1, nor how the hormone signals through the receptor
